tiprankstipranks
Vaxcyte completes enrollment of Phase 2 study evaluating VAX-24
PremiumThe FlyVaxcyte completes enrollment of Phase 2 study evaluating VAX-24
2M ago
Vaxcyte price target raised to $95 from $73 at Needham
PremiumThe Fly
Vaxcyte price target raised to $95 from $73 at Needham
2M ago
Vaxcyte price target raised to $98 from $76 at BTIG
PremiumThe Fly
Vaxcyte price target raised to $98 from $76 at BTIG
2M ago
Vaxcyte price target raised to $92 from $80 at BofA
PremiumThe FlyVaxcyte price target raised to $92 from $80 at BofA
3M ago
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
PremiumPress Releases
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
3M ago
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
PremiumPress Releases
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
3M ago
Vaxcyte announces common stock, warrants offering, no amount given
PremiumThe FlyVaxcyte announces common stock, warrants offering, no amount given
3M ago
Vaxcyte price target raised to $76 from $69 at BTIG
PremiumThe Fly
Vaxcyte price target raised to $76 from $69 at BTIG
3M ago
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
PremiumPress Releases
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100